# Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

> **NCT02678143** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 1 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Sirolimus
- **DRUG:** Fludarabine
- **RADIATION:** Total body irradiation
- **PROCEDURE:** Hematopoietic stem cell transplant

## Key facts

- **NCT ID:** NCT02678143
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-26
- **Primary completion:** 2020-04-03
- **Final completion:** 2021-11-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Closed early due to competing studies
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678143, "Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02678143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*